Study of tislelizumab plus chemo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that is advanced, has come back, or has spread, and cannot be cured with standard treatments like surgery or chemoradiation.
- You have not received any previous cancer treatment for this advanced stage.
- You have at least one tumor that can be measured on scans.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your organs are working well, based on blood tests taken within 2 weeks before starting the study drugs.
- If you could become pregnant, you must have a negative pregnancy test and use highly effective birth control during the study and for 120 days after the last dose of tislelizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.